Literature DB >> 19839227

Development of a novel immunoassay for the iron regulatory peptide hepcidin.

M Busbridge1, C Griffiths, D Ashby, D Gale, A Jayantha, A Sanwaiya, R S Chapman.   

Abstract

To date there have been few published immunoassays for the important iron regulator hepcidin. This study describes a novel competitive radioimmunoassay (RIA) for the bioactive hepcidin peptide. A rabbit anti-hepcidin polyclonal antibody was produced using synthetic hepcidin radiolabelled with 125I to produce a competitive RIA. Normal patient (n=47) samples were collected and assayed for hepcidin to determine a reference range. Other patient groups collected were ulcerative colitis (UC; n=40), iron deficiency anaemia (IDA; n=15), chronic kidney disease not requiring dialysis (CKD; n=45) and chronic kidney disease requiring dialysis (HCKD; n=94). Detection limit of the assay was determined as 0.6 ng/mL. Intra-assay precision was 5 ng/mL (7.2%) and 50 ng/mL (5.8%), interassay precision was 5 ng/mL (7.6%) and 50 ng/mL (6.7%). Analytical recovery was 98% (5 ng/mL), 94% (10 ng/mL) and 97% (50 ng/mL). The assay was linear up to 200 ng/mL. No demonstrable cross-reactivity with human insulin, glucagon I, angiotensinogen I, beta-defensin 1-4, alpha-defensin-1 and plectasin was observed. There was significant correlation (r=0.96, P < or = 0.0001) between the hepcidin RIA and an established hepcidin SELDI-TOF-MS method. Analysis of the normal human samples gave a reference range of 1.1-55 ng/mL for hepcidin. Further statistical evaluation revealed a significant difference between male and female hepcidin levels. There was significant correlation between hepcidin and ferritin in the control group (r=0.6, P < or = 0.0001). There was also a significant difference between the normal and disease groups (P < or = 0.0001). Healthy volunteers (n=10) showed a diurnal increase in plasma hepcidin at 4.00 pm compared to 8.00 am. A robust and optimised immunoassay for bioactive hepcidin has been produced and the patient sample results obtained further validates the important role of hepcidin in iron regulation, and will allow further investigation of this important peptide and its role in iron homeostasis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19839227     DOI: 10.1080/09674845.2009.11730263

Source DB:  PubMed          Journal:  Br J Biomed Sci        ISSN: 0967-4845            Impact factor:   3.829


  21 in total

1.  Benefits and risks of iron supplementation in anemic neonatal pigs.

Authors:  Paweł Lipinski; Rafał R Starzyński; François Canonne-Hergaux; Barbara Tudek; Ryszard Oliński; Paweł Kowalczyk; Tomasz Dziaman; Olivier Thibaudeau; Mikołaj A Gralak; Ewa Smuda; Jarosław Woliński; Agnieszka Usińska; Romuald Zabielski
Journal:  Am J Pathol       Date:  2010-09       Impact factor: 4.307

Review 2.  Hepcidin and iron homeostasis.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Biochim Biophys Acta       Date:  2012-01-26

3.  Presence of hepcidin-25 in biological fluids: bile, ascitic and pleural fluids.

Authors:  Jayantha Arnold; Arvind Sangwaiya; Vijay Manglam; Frank Geoghegan; Mark Thursz; Mark Busbridge
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

4.  Hepcidin levels in hereditary hyperferritinemia: Insights into the iron-sensing mechanism in hepatocytes.

Authors:  Jayantha Arnold; Arvind Sangwaiya; Vijay Manglam; Mark Thursz; Caroline Beaumont; Caroline Kannengiesser; Mark Busbridge
Journal:  World J Gastroenterol       Date:  2010-07-28       Impact factor: 5.742

5.  A novel monoclonal antibody immunoassay for the detection of human serum hepcidin.

Authors:  Peggy Schwarz; Pavel Strnad; Guido von Figura; Alfred Janetzko; Pierre Krayenbühl; Guido Adler; Hasan Kulaksiz
Journal:  J Gastroenterol       Date:  2010-12-07       Impact factor: 7.527

6.  Hepcidin in beta-thalassemia.

Authors:  Elizabeta Nemeth
Journal:  Ann N Y Acad Sci       Date:  2010-08       Impact factor: 5.691

7.  Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin.

Authors:  Sergei Nekhai; Min Xu; Altreisha Foster; Ishmael Kasvosve; Sharmin Diaz; Roberto F Machado; Oswaldo L Castro; Gregory J Kato; James G Taylor; Victor R Gordeuk
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

8.  Optimal iron fortification of maternal diet during pregnancy and nursing for investigating and preventing iron deficiency in young rhesus monkeys.

Authors:  Christopher L Coe; Gabriele R Lubach; Mark Busbridge; Richard S Chapman
Journal:  Res Vet Sci       Date:  2013-01-10       Impact factor: 2.534

9.  Intravenous iron therapy in patients with idiopathic pulmonary arterial hypertension and iron deficiency.

Authors:  Gerrina Ruiter; Emmy Manders; Chris M Happé; Ingrid Schalij; Herman Groepenhoff; Luke S Howard; Martin R Wilkins; Harm J Bogaard; Nico Westerhof; Willem J van der Laarse; Frances S de Man; Anton Vonk-Noordegraaf
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

10.  Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias.

Authors:  Elizabeta Nemeth
Journal:  Adv Hematol       Date:  2009-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.